DongKook Pharmaceutical Co (XKRX:086450) 5-Year EBITDA Growth Rate : 29.80% (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is DongKook Pharmaceutical Co 5-Year EBITDA Growth Rate?

DongKook Pharmaceutical Co's EBITDA per Share for the three months ended in Dec. 2024 was ₩536.05.

During the past 12 months, DongKook Pharmaceutical Co's average EBITDA Per Share Growth Rate was 33.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 9.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 29.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of DongKook Pharmaceutical Co was 72.40% per year. The lowest was -33.50% per year. And the median was 13.00% per year.

Competitive Comparison of DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

DongKook Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

DongKook Pharmaceutical Co (XKRX:086450) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

DongKook Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of DongKook Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

DongKook Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DongKook Pharmaceutical Co Ltd (XKRX:086450) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Dongkook Building 997-8 Daechi 3-dong, Kangnam-gu, Seoul, KOR, 135-502

Website

http://www.dkpharm.co.kr

DongKook Pharmaceutical Co Ltd is a part of the healthcare industry based in Korea. Being a pharmaceutical company, its activities are focused on the research and development of drugs. The company produces superior medicines used favorably by consumers such as Madecassol, which is a drug for wounds and Oramedy, which is a drug for treating stomatitis. It also owns a prefilled syringe system in its second factory, through which it produces various kinds of ultramodern injection agents.

DongKook Pharmaceutical Co Headlines

No Headlines